医学
沙利度胺
化疗
内科学
肿瘤科
维持疗法
外科
肺癌
诱导化疗
多发性骨髓瘤
作者
Afshin Dowlati,Shanmuga Subbiah,Matthew M. Cooney,Kimberly Rutherford,Tarek Mekhail,Pingfu Fu,Robert A. Chapman,Anne Ness,Tania Cortas,Joel Saltzman,Nathan Levitan,Gregory V. Warren
出处
期刊:Lung Cancer
[Elsevier]
日期:2007-06-01
卷期号:56 (3): 377-381
被引量:30
标识
DOI:10.1016/j.lungcan.2007.01.020
摘要
Extensive-stage small cell lung cancer (SCLC) is a highly aggressive malignancy for which little therapeutic progress has been made over the past 20 years. SCLC is a highly angiogenic tumor and targeting angiogenesis is being investigated. The putative mechanism of action of thalidomide is through inhibition of new blood vessel formation. This trial was designed to evaluate thalidomide in ES-SCLC.Patients who had received first-line chemotherapy without disease progression were eligible. Patients received thalidomide 200 mg daily as maintenance therapy starting 3-6 weeks after completion of chemotherapy.Thirty patients were enrolled. Toxicity was minimal with grade 1 neuropathy in 27% of patients and only one case of grade 3 neuropathy. Median survival from time of initiation of induction chemotherapy was 12.8 months (95% CI: 10.1-15.8 months) and 1-year survival of 51.7% (95% CI: 32.5-67.9%). Median duration on thalidomide was 79 days.Thalidomide 200mg daily is well tolerated when given as maintenance therapy for ES-SCLC after induction chemotherapy. Further evaluation of anti-angiogenic agents in SCLC is warranted.
科研通智能强力驱动
Strongly Powered by AbleSci AI